Clopidogrel is an antiplatelet agent sold under the tradnames Plavix?, Iscover?, Clopilet? and Ceruvin? . It prevents the formation of platelets, and is prescribed to reduce the chance of blood clot formation in several clinical contexts. Over 100 million prescriptions for clopidogrel have been written since its introduction in 2000. It is now known that some individuals have diminished or no response to clopidogrel due to genetic variations.This test determines whether the patient has a genetic variant that that causes them to be a poor metabolizer or non-matabolizer of clopidogrel. Clopidogrel has diminished or no effect in these individuals. Based on the results of this genetic test, their physician may adjust their dosage or choose other treatment regimes.
We have not reviewed this DNA test yet. If you have taken this test, please scroll down and click “Add your review.” All DNA tests that have not been reviewed receive a default score of 6/10 until reader reviews change the score.
Clopidogrel is an antiplatelet agent sold under the tradnames Plavix?, Iscover?, Clopilet? and Ceruvin? . It prevents the formation of platelets, and is prescribed to reduce the chance of blood clot formation in several clinical contexts. Over 100 million prescriptions for clopidogrel have been written since its introduction in 2000. It is now known that some individuals have diminished or no response to clopidogrel due to genetic variations.This test determines whether the patient has a genetic variant that that causes them to be a poor metabolizer or non-matabolizer of clopidogrel. Clopidogrel has diminished or no effect in these individuals. Based on the results of this genetic test, their physician may adjust their dosage or choose other treatment regimes.
Clopidogrel is an antiplatelet agent sold under the tradnames Plavix?, Iscover?, Clopilet? and Ceruvin? . It prevents the formation of platelets, and is prescribed to reduce the chance of blood clot formation in several clinical contexts. Over 100 million prescriptions for clopidogrel have been written since its introduction in 2000. It is now known that some individuals have diminished or no response to clopidogrel due to genetic variations.This test determines whether the patient has a genetic variant that that causes them to be a poor metabolizer or non-matabolizer of clopidogrel. Clopidogrel has diminished or no effect in these individuals. Based on the results of this genetic test, their physician may adjust their dosage or choose other treatment regimes.
